What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis St. Louis, MO